Recent Advances in Molecular Mechanisms and Targeted Therapies for Leukemia
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".
Deadline for manuscript submissions: 30 August 2025 | Viewed by 113
Special Issue Editor
Interests: molecular area of acute myeloid leukemia; myelodysplastic sydnrome; non-Hodgkin's lymphoma
Special Issue Information
Dear Colleagues,
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While survival for younger patients over the last several decades has improved nearly sixfold with the optimization of intensive induction chemotherapy and allogeneic stem cell transplantation, the understanding of the molecular characteristics of AML has led to the development of various therapeutic options. For instance, low-intensity therapy with hypomethylating agents and venetoclax has improved prognosis in AML, and other targeted oral agents against driver mutations were evaluated so that the options have opened a novel therapeutic field in AML treatment.
Recently, several questions have arisen, such as how to best sequence therapy and how to combine therapies in those who achieve remission and cannot undergo allogeneic stem cell transplantation due to an accelerated increase in treatment options.
The Special Issue provides the opportunity to describe the molecular mechanisms of pathobiology and novel therapeutic options in the field of AML.
Dr. Moo Kon Song
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- targeted therapy
- acute myeloid leukemia
- genetic mutations
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
